NT157 是一种口服生物可利用的间充质-上皮转化 (MET) TKI，主要针对具有 METex14 跳跃突变的特定 NSCLC 患者开发。

NT157 is a small molecule tyrphostin targeting IRS protein and has the potential to inhibit IGF-1R and STAT3 signaling pathways in TME cancer cells and stromal cells, resulting in decreased cancer cell survival.

NT157 treatment resulted in dose-dependent inhibition of IGF1R activation, suppression of IRS protein expression, inhibition of IGF1-induced AKT activation, but increased ERK activation in NT157-treated cells in vitro[2].

NT157 suppressed androgen-responsive growth, delayed CRPC progression of LNCaP xenografts, and suppressed PC3 tumor growth alone and in combination with docetaxel[2].

1384426-12-3

C16H14BrNO5S

412.25

Ethanol:25.83mg/ml(186.78 mM)
DMSO:77 mg/ml(186.78 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years